Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC) - 21/06/16
Supported in part by a Damon Runyon Cancer Research Foundation Clinical Investigator Award (CI-54-11 to Dr Tang). |
|
Disclosure: Drs Tang, Chang, and Oro have been investigators in studies sponsored by Genentech. Dr Aasi has been on the advisory board of Genentech. Dr Oro has also been an investigator in studies sponsored by Infinity and Novartis and Dr Chang is also a clinical investigator for studies sponsored by Novartis and Lilly. Dr Kwon, Dr Kim, Dr Ally, and Ms Bailey-Healy have no conflicts of interest to declare. |
Vol 75 - N° 1
P. 213-215 - juillet 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?